Pathogenesis of the viral hemorrhagic fevers

Annual Review of Pathology: Mechanisms of Disease

Volumn 8, Issue , 2013, Pages 411-440

  Paessler, Slobodan ^a   Walker, David H ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Arenaviruses; Dengue; Filoviruses; Hemorrhage; Vascular permeability; Yellow fever

Indexed keywords

CD71 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN VP24; PROTEIN VP30; PROTEIN VP40; RNA DIRECTED RNA POLYMERASE; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ABDOMINAL PAIN; AMERICAN HEMORRHAGIC FEVER; ANOREXIA; ANURIA; ARENAVIRUS INFECTION; BOLIVIAN HEMORRHAGIC FEVER; CENTRAL AFRICAN REPUBLIC; CHILL; CLINICAL FEATURE; CONGO; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; COUGHING; CYTOKINE RELEASE; DENDRITIC CELL; DENGUE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DOWN REGULATION; EPISTAXIS; FEVER; FILOVIRUS; GUINEA; HEADACHE; HEMATEMESIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LASSA FEVER; LEUKOPENIA; LIBERIA; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MACROPHAGE; MALAISE; MALI; MARBURG HEMORRHAGIC FEVER; MEGAKARYOCYTE; MELENA; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; NIGERIA; NONHUMAN; NOSE OBSTRUCTION; PATHOGENESIS; PHOTOPHOBIA; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SENEGAL; SHOCK; SIERRA LEONE; TACHYPNEA; THROMBOCYTOPENIA; VENEZUELAN HEMORRHAGIC FEVER; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS HEMORRHAGIC FEVER; VIRUS IMMUNITY; VOMITING; YELLOW FEVER; ANIMAL; PATHOLOGY; PHYSIOLOGY; RNA VIRUS; VIROLOGY;

ANIMALS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; RNA VIRUSES;

MLCS; MLOWN;

EID: 84875904431     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-164041     Document Type: Review

References (155)

1. Schnittler HJ, Feldmann H. 2003. Viral hemorrhagic fever - a vascular disease? Thromb. Haemost. 89:967-722
2. Peters CJ, Zaki SR. 2002. Role of the endothelium in viral hemorrhagic fevers. Crit. CareMed. 30(Suppl. 5):268-733
3. Chen JP, Cosgriff TM. 2000. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul. Fibrinolysis 11:461-833
4. Peters CJ, Zaki SR. 2011. Overview of viral hemorrhagic fevers. In Tropical Infectious Diseases, ed. RL Guerrant, DHWalker, PFWeller, pp. 441-48. London: Elsevier Saunders. 3rd ed..
5. Wahl-Jensen V, Peters CJ, Sanchez A, Rollin P, Jahrling PB, et al. 2011. Filovirus infections. In Tropical Infectious Diseases, ed. RL Guerrant, DH Walker, PF Weller, pp. 483-91. London: Elsevier Saunders. 3rd ed..
6. Leroy EM, Gonzalez J-P, Baize S. 2011. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin. Microbiol. Infect. 17:964-766
7. Feldmann H, Geisbert TW. 2011. Ebola haemorrhagic fever. Lancet 377:849-622
8. Villinger F, Rollin PE, Brar SS, Chikkala NF,Winter J, et al. 1999. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor αassociated with fatal Ebola virus infection. J. Infect. Dis. 179:188-911
9. Bwaka MA, Bonnet M-J, Calain P, Colebunders R, De Roo A, et al. 1999. Ebola hemorrhagic fever in Kikwit,Democratic Republic of theCongo: clinical observations in 103 patients. J. Infect. Dis. 179(Suppl. 1):1-77
10. Korpeter MG, Bausch DG, Bray M. 2011. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 204(Suppl. 3):810-166
11. Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, et al. 2011. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204:957-677
12. Wahl-Jensen V, Afanasieva TA, Seebach J, Str öher U, Feldmann H, Schnittler H-J. 2005. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79:10442-500
13. Wahl-Jensen V, Kurtz SK, Hazelton PR, Schnittler H-J, Ströher U, et al. 2005. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 79:2413-199
14. Zaki SR, Peters CJ. 1997. Viral hemorrhagic fevers. In Diagnostic Pathology of Infectious Diseases, ed. DH Connor, FW Chandler, DA Schwartz, HJ Manz, EE Lack, pp. 347-64. New York: McGraw Hilll
15. Zaki SR, Kilmarx PH. 1997. Ebola virus hemorrhagic fever. In Pathology of Emerging Infections, ed. CR Horsburgh Jr, AM Nelson, pp. 299-312. Washington, DC: Am. Soc. Microbiol..
16. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 2010. Human fatal Zaire ebolavirus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4:e8377
17. Baize S, Leroy EM, Georges AJ, Georges-Courbot M-C, Capron M, et al. 2002. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128:163-688
18. Baize S, Leroy EM, Georges-Courbot M-C, Capron M, Lansoud-Soukate J, et al. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5:423-266
19. Wauquier N, Padilla C, Becquart P, Leroy E, Vieillard V. 2010. Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics 62:767-711
20. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Investig. 80:171-866
21. Hensley LE, Alves DA, Geisbert JB, Fritz EA, Reed C, et al. 2011. Pathogenesis ofMarburg hemorrhagic fever in cynomolgus macaques. J. Infect. Dis. 204:1021-31SS
22. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques. Am. J. Pathol. 163:2347-700
23. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. 2004. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol. 17:390-4000
24. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. 2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188:1618-299
25. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, et al. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models. Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 163:2371-822
26. Ebihara H, Rockx B, Marzi A, Feldmann F, Haddock E, et al. 2011. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J. Infect. Dis. 204:991-99SS
27. Kortepeter MG, Lawler JV, Honko A, Bray M, Johnson JC, et al. 2011. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J. Infect. Dis. 204:1000-10SS
28. Jaax NK, Davis KJ, Geisbert TW, Vogel P, Jaax GP, et al. 1996. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120:140-555
29. Str öher U, West E, Bugany H, Klenk H-D, Schnittler H-J, Feldmann H. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75:11025-333
30. Feldman H, Bugany H, Mahner F, Klenk H-D, Drenckhahn D, Schnittler H-J. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70:2208-144
31. Böckeler M, Str öher U, Seebach J, Afanasieva T, Suttorp N, et al. 2007. Breakdown of paraendothelial barrier function during Marburg virus infection is associated with early tyrosine phosphorylation of platelet endothelial cell adhesion molecule 1. J. Infect. Dis. 196:337-46SS
32. Olejnik J, Ryabchikova E, Corley RB, Mühlberger E. 2011. Intracellular events and cell fate in filovirus infection. Viruses 3:1501-311
33. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, et al. 2007. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196(Suppl. 2):390-999
34. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953-588
35. JinH, Yan Z, Prabhakar BS, Feng Z, Ma Y, et al. 2010. TheVP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J. Gen. Virol. 91:352-611
36. MacNamara FN. 1957.Aclinico-pathological study of yellow fever in Nigeria. West Afr. Med. J. 6:137-466
37. Klotz O, Belt TH. 1930. The pathology of the liver in yellow fever. Am. J. Pathol. 6:663-899
38. Quaresma JAS, Barros VLRS, Pagliari C, Fernandes ER, Andrade HF Jr, et al. 2007. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans. R. Soc. Trop. Med. Hyg. 101:161-688
39. Monath TP, Ballinger ME, Miller BR, Salaun JJ. 1989. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am. J. Trop. Med. Hyg. 40:663-688
40. Quaresma JAS, Barros VLRS, Fernandes ER, Pagliari C, Guedes F, et al. 2006. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res. 116:91-977
41. Jones EMM, Wilson DC. 1972. Clinical features of yellow fever cases at Vom Christian Hospital during the 1969 epidemic on the Jos Plateau, Nigeria. Bull. World Health Organ. 46:653-577
42. EltonNW, Romero A, Trejos A. 1955. Clinical pathology of yellow fever. Am. J. Clin. Pathol. 25:135-466
43. Monath TP, Barrett ADT. 2003. Pathogenesis and pathophysiology of yellow fever. In Advances in Virus Research, vol. 20, ed. K Maramorosch, A Shatkin, F Murphy, pp. 343-95. London: Elsevierr
44. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB. 1981. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 30:431-433
45. KlotzO, BeltTH. 1930. Regeneration of liver and kidney following yellow fever. Am. J. Pathol. 6:689-977
46. Li G, Duan T, Wu X, Tesh RB, Soong L, Xiao S-Y. 2008. Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes. Int. J. Clin. Exp. Pathol. 1:169-799
47. ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, et al. 2004. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J. Infect. Dis. 190:1821-277
48. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11:532-433
49. Halstead SB. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med. 42:350-622
50. Srikiatkhachorn A. 2009. Plasma leakage in dengue haemorrhagic fever. Thromb. Haemost. 102:1042-499
51. Rothman AL. 2010. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr. Top. Microbiol. Immunol. 338:83-988
52. Rosen L. 1977. The emperor's new clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 26:337-433
53. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, et al. 2005. Dengue virus (DV) enhancing antibody activity in pre-illness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J. Infect. Dis. 192:510-200
54. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6:e10001711
55. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, et al. 2011. B cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204:1514-222
56. Duangchinda T, DejnirattisaiW, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, et al. 2010. Immunodominant T cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. USA 107:16922-277
57. Bhamarpravati N, Tuchinda P, Boonyapaknavik V. 1967. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann. Trop. Med. Parasitol. 61:500-100
58. BurkeT. 1968 Dengue haemorrhagic fever: a pathological study. Trans. R. Soc. Trop. Med. Hyg. 62:682-922
59. Fresh JW, Reyes V, Clarke EJ, Uylangco CV. 1969. Philippine hemorrhagic fever: a clinical, laboratory, and necropsy study. J. Lab. Clin. Med. 73:451-588
60. Nascimento EJM, Silva AM, Cordeiro MT, Brito CA, Gil LHVG, et al. 2009. Alternative complement pathway deregulation is correlated with dengue severity. PLoS ONE 4:e67822
61. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, et al. 2007. Natural history of plasma leakage in dengue hemorrhagic fever. A serial ultrasonographic study. Pediatr. Infect. Dis. J. 26:283-900
62. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, et al. 2010. Report of an NIAID workshop on dengue animal models. Vaccine Conf. Rep. 28:4229-344
63. Onlamoon N, Noisakran S, Hsiao H-M, Duncan A, Villinger F, et al. 2010. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 115:1823-344
64. Shresta S, ShararKL, PrigozhinDM, Beatty PR,HarrisE. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-177
65. Tan GK, Ng JKW, Trasti SL, Schul W, Yip G, Alonso S. 2010. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4:e6722
66. Kuruvilla JG, Troyer RM, Devi S, Akkina R. 2007. Dengue virus infection and immune response in humanized RAG2γc (RAG-hu) mice. Virology 369:143-522
67. Mota J, Rico-Hesse R. 2009. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J. Virol. 83:8638-455
68. Halstead SB. 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140:527-333
69. WilliamsKL, Zompi S, Beatty PR,HarrisE. 2009.Amousemodel for studying dengue virus pathogenesis and immune response. Ann. N.Y. Acad. Sci. 1171:12-233
70. WilliamsKL, Zompi S, Beatty PR,HarrisE. 2009.Amousemodel for studying dengue virus pathogenesis and immune response: erratum. Ann. N.Y. Acad. Sci. 1179:234-455
71. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, Kalayanarooj S, Libraty DH, et al. 2007. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J. Virol. 81:1592-6000
72. Assunção-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, et al. 2010. Contribution of macrophage inhibitory factor to the pathogenesis of dengue virus infection. FASEB J. 24:218-288
73. Mills JN, Ellis BA, Childs JE, McKee KT Jr, Maiztegui JI, et al. 1994. Prevalence of infection with Junin virus in rodent populations in the epidemic area of Argentine hemorrhagic fever. Am. J. Trop. Med. Hyg. 51:554-622
74. Parodi AS, Coto CE, Boxaca M, Lajmanovich S, Gonzalez S. 1966. Characteristics of Junin virus. Etiological agent of Argentine hemorrhagic fever. Arch. Gesamte Virusforsch. 19:393-4022
75. Gonzalez JP, Bowen MD, Nichol ST, Rico-Hesse R. 1996. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology 221:318-244
76. Johnson KM,McCormick JB,Webb PA, Smith ES, Elliott LH, King IJ. 1987. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155:456-644
77. Buchmeier MJ, de la Torre JC, Peters CJ. 2007. Arenaviridae: the viruses and their replication. In Field's Virology, ed. DM Knipe, PM Howley, pp. 1635-68. Philadelphia: Lippincott, Williams &Wilkinss
78. Tortorici MA, Albarino CG, Posik DM, Ghiringhelli PD, Lozano ME, et al. 2001. Arenavirus nucleocapsid protein displays a transcriptional antitermination activity in vivo. Virus Res. 73:41-555
79. Meyer BJ, Southern PJ. 1994. Sequence heterogeneity in the termini of lymphocytic choriomeningitis virus genomic and antigenomic RNAs. J. Virol. 68:7659-644
80. Beyer WR, Popplau D, Garten W, von Laer D, Lenz O. 2003. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 77:2866-722
81. Lenz O, terMeulen J, Klenk HD, Seidah NG, Garten W. 2001. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. USA 98:12701-55
82. Pinschewer DD, Perez M, Sanchez AB, de la Torre JC. 2003. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. USA 100:7895-9000
83. Poch O, Sauvaget I, Delarue M, Tordo N. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:3867-744
84. PerezM, Craven RC, de la Torre JC. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. USA 100:12978-833
85. Strecker T, Eichler R, Meulen J,Weissenhorn W, Dieter Klenk H, et al. 2003. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J. Virol. 77:10700-55
86. Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J. 2006. Cellular factors required for Lassa virus budding. J. Virol. 80:4191-955
87. Enria DA, Briggiler AM, Pini N, Levis S. 2001. Clinical manifestations of New World hantaviruses. Curr. Top. Microbiol. Immunol. 256:117-344
88. Enria DA, Barrera Oro JG. 2002. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263:239-611
89. Peters CJ. 2002. Human infection with arenaviruses in the Americas. Curr. Top. Microbiol. Immunol. 262:65-744
90. Gunther S, Lenz O. 2004. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41:339-900
91. Geisbert TW, Jahrling PB. 2004. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10:110-21SS
92. Lecompte E, Fichet-Calvet E, Daffis S, Koulemou K, Sylla O, et al. 2006. Mastomys natalensis and Lassa fever,West Africa. Emerg. Infect. Dis. 12:1971-744
93. Peralta LA, Laguens RP, Cossio PM, Sabattini MS,Maiztegui JI, Arana RM. 1979. Presence of viral particles in the salivary gland of Calomys musculinus infected with Junin virus by a natural route. Intervirology 11:111-166
94. Douglas R, Wiebenga N, Couch R. 1965. Bolivian hemorrhagic fever probably transmitted by personal contact. Am. J. Epidemiol. 82:85-911
95. Johnson KM, Halstead SB, Cohen SN. 1967. Hemorrhagic fevers of Southeast Asia and South America: a comparative appraisal. Prog. Med. Virol. 9:105-588
96. Chastel C. 1993. Present status of zoonotic hemorrhagic fevers of South America. Bull. Soc. Pathol. Exot. 86:455-599
97. Salas R, de Manzione N, Tesh RB, Rico-Hesse R, Shope RE, et al. 1991. Venezuelan haemorrhagic fever. Lancet 338:1033-366
98. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, et al. 1982. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 107:349-566
99. Johnson KM,McCormick JB,Webb PA, Smith ES, Elliott LH, King IJ. 1987. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155:456-644
100. Briggiler A, Levis S, Enria D, Ambrosio A,Maiztegui J. 1990. Argentine hemorrhagic fever in pregnant women. Medicina 50:4433
101. Weissenbacher MC, de Guerrero LB, Boxaca MC. 1975. Experimental biology and pathogenesis of Junin virus infection in animals and man. Bull. World Health Organ. 52:507-155
102. Barrios HA, Rondinone SN, Blejer JL, Giovanniello OA, Nota NR. 1982. Development of specific immune response in mice infected with Junin virus. Acta Virol. 26:156-644
103. Weissenbacher MC, Calello MA, Quintans CJ, Panisse H, Woyskowsky NM, Zannoli VH. 1983. Junin virus infection in genetically athymic mice. Intervirology 19:1-55
104. Campetella OE, Galassi NV, Sanjuan N, Barrios HA. 1988. Susceptible adult murine model for Junin virus. J Med. Virol. 26:443-511
105. Kenyon RH, Green DE,Maiztegui JI, Peters CJ. 1988. Viral strain dependent differences in experimental Argentine hemorrhagic fever. Intervirology 29:133-433
106. YunNE, LindeNS, Dziuba N, ZacksMA, Smith JN, et al. 2008. Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am. J. Trop. Med. Hyg. 79:275-822
107. Aronson JF, Herzog NK, Jerrells TR. 1994. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. Am. J. Pathol. 145:228-355
108. RemesarMC, Blejer JL, Lerman GD, Dejean C, Nejamkis MR. 1989. Protection against encephalitis in rats caused by a pathogenic strain of the Junin virus, using peripheral inoculation of an attenuated strain. Rev. Argent. Microbiol. 21:120-266
109. Weissenbacher MC, Calello MA, Colillas OJ, Rondinone SN, Frigerio MJ. 1979. Argentine hemorrhagic fever: a primate model. Intervirology 11:363-655
110. McKee KT Jr, Green DE, Mahlandt BG, Bagley LR, Lyerly WH Jr, et al. 1985. Infection of Cebus monkeys with Junin virus. Medicina 45:144-522
111. McKee KT Jr, Mahlandt BG, Maiztegui JI, Eddy GA, Peters CJ. 1985. Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J. Infect. Dis. 152:218-211
112. Avila MM, Samoilovich SR, Laguens RP, Merani MS, Weissenbacher MC. 1987. Protection of Junin virus-infected marmosets by passive administration of immune serum: association with late neurologic signs. J. Med. Virol. 21:67-744
113. Carballal G, Oubina JR, Molinas FC, Nagle C, de la Vega MT, et al. 1987. Intracerebral infection of Cebus apella with the XJ clone 3 strain of Junin virus. J. Med. Virol. 21:257-688
114. Kenyon RH, McKee KT Jr, Maiztegui JI, Green DE, Peters CJ. 1986. Heterogeneity of Junin virus strains. Med. Microbiol. Immunol. 175:169-722
115. Campetella OE, Barrios HA, Galassi NV. 1988. Junin virus-induced delayed-type hypersensitivity suppression in adult mice. J. Med. Virol. 25:227-355
116. Kenyon RH, Peters CJ. 1986. Cytolysis of Junin infected target cells by immune guinea pig spleen cells. Microb. Pathog. 1:453-644
117. Kenyon RH, Green DE, Eddy GA, Peters CJ. 1986. Treatment of Junin virus-infected guinea pigs with immune serum: development of late neurological disease. J. Med. Virol. 20:207-188
118. McKee KT Jr, Mahlandt BG, Maiztegui JI, Green DE, Peters CJ. 1987. Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaques. J. Med. Virol. 22:99-1111
119. Kenyon RH, McKee KT Jr, Zack PM, Rippy MK, Vogel AP, et al. 1992. Aerosol infection of rhesus macaques with Junin virus. Intervirology 33:23-311
120. Elsner B, Boxaca MC, Weissenbacher M, De Guerrero LB. 1976. Experimental Junin virus infection of guinea pigs. I. Pathological anatomy. Medicina 36:197-2066
121. Salazar M, Yun NE, Poussard AL, Smith JN, Smith JK, et al. 2012. Effect of ribavirin on Junin virus infection in guinea pigs. Zoonoses Public Health 59:278-855
122. Seregin AV, Yun NE, Poussard AL, Peng BH, Smith JK, et al. 2010. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine 28:4713-188
123. Lopez N, Scolaro L, Rossi C, Jacamo R, Candurra N, et al. 2000. Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J. Gen. Virol. 81:1273-811
124. Peters CJ, Jahrling PB, LiuCT, Kenyon RH, McKeeKTJr, Barrera Oro JG. 1987. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134:5-688
125. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, et al. 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446:92-966
126. Martinez MG, Cordo SM, Candurra NA. 2007. Characterization of Junin arenavirus cell entry. J. Gen. Virol. 88:1776-844
127. Gonzalez PH, Cossio PM, Arana R, Maiztegui JI, Laguens RP. 1980. Lymphatic tissue in Argentine hemorrhagic fever. Pathologic features. Arch. Pathol. Lab. Med. 104:250-544
128. Gomez RM, Pozner RG, Lazzari MA, D'Atri LP, Negrotto S, et al. 2003. Endothelial cell function alteration after Junin virus infection. Thromb. Haemost. 90:326-333
129. Kawai T, Akira S. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N.Y. Acad. Sci. 1143:1-200
130. Barbalat R, Lau L, Locksley RM, Barton GM. 2009. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat. Immunol. 10:1200-77
131. Marq JB, Kolakofsky D, Garcin D. 2010. Unpaired 5- ppp-nucleotides, as found in arenavirus dsRNA panhandles, are not recognized by RIG-I. J. Biol. Chem. 285:18208-166
132. Levy DE, Marie I, Smith E, Prakash A. 2002. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. 22:87-933
133. Bowie AG, Unterholzner L. 2008. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8:911-222
134. Versteeg GA, Garcia-Sastre A. 2010. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 13:508-166
135. Martinez-SobridoL,GiannakasP,Cubitt B, Garcia-Sastre A, de la Torre JC. 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81:12696-7033
136. Martinez-Sobrido L, Zuniga EI, RosarioD,Garcia-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80:9192-999
137. Huang C, Kolokoltsova OA, Yun NE, Seregin AV, Poussard AL, et al. 2012. Junin virus infection activates the type I interferon pathway in a RIG-1-dependent manner. PLoS Negl. Trop. Dis. 6:e16599
138. Heller MV, Saavedra MC, Falcoff R, Maiztegui JI, Molinas FC. 1992. Increased tumor necrosis factor αlevels in Argentine hemorrhagic fever. J. Infect. Dis. 166:1203-44
139. Levis SC, Saavedra MC, Ceccoli C, Feuillade MR, Enria DA, et al. 1985. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J. Interferon Res. 5:383-899
140. Levis SC, Saavedra MC, Ceccoli C, Falcoff E, Feuillade MR, et al. 1984. Endogenous interferon in Argentine hemorrhagic fever. J. Infect. Dis. 149:428-333
141. Ferbus D, Saavedra MC, Levis S, Maiztegui J, Falcoff R. 1988. Relation of endogenous interferon and high levels of 2-5-oligoadenylate synthetase in leukocytes from patients with Argentine hemorrhagic fever. J. Infect. Dis. 157:1061-644
142. Marta RF, Montero VS, Hack CE, Sturk A, Maiztegui JI, Molinas FC. 1999. Proinflammatory cytokines and elastase-α-1-antitrypsin in Argentine hemorrhagic fever. Am. J. Trop. Med. Hyg. 60:85-899
143. Marta RF, Montero VS, Molinas FC. 1998. Systemic disorders in Argentine haemorrhagic fever. Bull. Inst. Pasteur 96:115-244
144. Canonico PG, Kende M, Luscri BJ, Huggins JW. 1984. In vivo activity of antivirals against exotic RNA viral infections. J. Antimicrob. Chem. 14(Suppl. A):27-411
145. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. 2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170:2797-8011
146. Maiztegui JI, FernandezNJ, de Damilano AJ. 1978. Reduction in themortality of American hemorrhagic fever (AHF) during treatment with immune serums. Medicina 38:7433
147. Enria DA, Maiztegui JI. 1994. Antiviral treatment of Argentine hemorrhagic fever. Antivir. Res. 23:23-311
148. Kenyon RH, Peters CJ. 1989. Actions of complement on Junin virus. Rev. Infect. Dis. 11(Suppl. 4):771-766
149. Molinas FC, de Bracco MM, Maiztegui JI. 1989. Hemostasis and the complement system in Argentine hemorrhagic fever. Rev. Infect. Dis. 11(Suppl. 4):762-700
150. de BraccoMM, Rimoldi MT, Cossio PM, Rabinovich A, Maiztegui JI, et al. 1978. Argentine hemorrhagic fever. Alterations of the complement system and anti-Junin-virus humoral response. N. Eng. J. Med. 299:216-211
151. Muller S, Geffers R, Gunther S. 2007. Analysis of gene expression in Lassa virus-infected HuH-7 cells. J. Gen. Virol. 88:1568-755
152. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, et al. 2010. Mice lacking α/β and γ interferon receptors are susceptible to Junin virus infection. J. Virol. 84:13063-677
153. Lukashevich IS, Maryankova R, Vladyko AS, Nashkevich N, Koleda S, et al. 1999. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-αgene expression. J. Med. Virol. 59:552-600
154. Walker DH, Murphy FA. 1987. Pathology and pathogenesis of arenavirus infections. Curr. Top. Microbiol. Immunol. 133:89-1133
155. Pozner RG, Ure AE, Jaquenod de Giusti C, D'Atri LP, Italiano JE, et al. 2010. Junin virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling. PLoS Pathog. 6:e10008477